Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.59, denoting a -2.36% move from the preceding trading day.
Aquatic Capital Management LLC Acquires Shares of 29,596 Vertex Pharmaceuticals Incorporated $VRTX
Aquatic Capital Management LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 29,596 shares of the pharmaceutical company's stock, valued at approximately $11,591,000. A number of other institutional investors
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $492.38, representing a -1.36% change from its previous close.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results
Vertex Pharmaceuticals (VRTX) shares are soaring after the company said it achieved "remarkable" results from a new clinical trial.
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
